View Item 

Show simple item record

Depression, antidepressant medication, and functioning outcomes among pregnant women

dc.contributor.authorMarcus, Sheila M.
dc.contributor.authorFlynn, Heather A.
dc.date.accessioned2017-01-10T19:06:34Z
dc.date.available2017-01-10T19:06:34Z
dc.date.issued2008-03
dc.identifier.citationMarcus, Sheila M.; Flynn, Heather A. (2008). "Depression, antidepressant medication, and functioning outcomes among pregnant women." International Journal of Gynecology & Obstetrics 100(3): 248-251.
dc.identifier.issn0020-7292
dc.identifier.issn1879-3479
dc.identifier.urihttps://hdl.handle.net/2027.42/135376
dc.description.abstractObjectivesTo describe prenatal patterns of antidepressant use and their relationship to depression in pregnancy.MethodsA total of 276 high risk women completed a structured clinical interview to investigate use of antidepressant medication.ResultsOf the women interviewed, 13% (n = 36) reported current use of antidepressant medication; there were no differences in depression or health functioning outcomes between women taking antidepressants and those not using them.ConclusionsMonitoring the depressive symptoms of women using pharmacotherapy during pregnancy is important to optimize their treatment.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherPrevalence
dc.subject.otherPregnancy
dc.subject.otherPharmacotherapy
dc.subject.otherDepression
dc.subject.otherAntidepressants
dc.titleDepression, antidepressant medication, and functioning outcomes among pregnant women
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelObstetrics and Gynecology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan Depression Center, University of Michigan Medical School, Ann Arbor, MI, USA
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135376/1/ijgo248.pdf
dc.identifier.doi10.1016/j.ijgo.2007.09.016
dc.identifier.sourceInternational Journal of Gynecology & Obstetrics
dc.identifier.citedreferenceSuri R., Altshuler L., Hendrick V., Rasgon N., Lee E., Mintz J.. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Women Ment Health. 7: 2004; 192 – 200
dc.identifier.citedreferenceHueston W.J., Kasik‐Miller S.. Changes in functional health status during normal pregnancy. J Fam Pract. 47: 1998; 209 – 212
dc.identifier.citedreferenceFlynn H.A., Blow F.C., Marcus S.M.. Rates and predictors of depression treatment among pregnant women in hospital‐affiliated obstetrics practices. Gen Hosp Psych. 28: 2006; 289 – 295
dc.identifier.citedreferenceCohen L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 295: 2006; 499 – 507
dc.identifier.citedreferenceAltshuler L.L., Cohen L., Szuba M.P., Burt V.K., Gitlin M., Mintz J.. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatr. 153: 1996; 592 – 606
dc.identifier.citedreferenceAddis A., Koren G.. Safety of fluoxetine during the first trimester of pregnancy: a meta‐analytical review of epidemiological studies. Psychol Med. 30: 2000; 89 – 94
dc.identifier.citedreferenceCohen L.S., Heller V.L., Bailey J.W., Grush L., Ablon J.S., Bouffard S.M.. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 48: 2000; 996 – 1000
dc.identifier.citedreferenceGoldstein D.J.. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol. 15: 1995; 417 – 420
dc.identifier.citedreferenceNulman I., Koren G.. The safety of fluoxetine during pregnancy and lactation. Teratology. 53: 1996; 304 – 308
dc.identifier.citedreferenceEricson A., Kallen B., Wiholm B.. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 55: 1999; 503 – 508
dc.identifier.citedreferenceChambers C.D., Hernandez‐Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin‐reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med. 354: 2006; 579 – 587
dc.identifier.citedreferenceHendrick V., Smith L.M., Suri R., Hwang S., Haynes D., Altshuler L.. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 188: 2003; 812 – 815
dc.identifier.citedreferenceKallen B.. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 158: 2004; 312 – 316
dc.identifier.citedreferenceNordeng H., Lindemann R., Perminov K.V., Reikvam A.. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 90: 2001; 288 – 291
dc.identifier.citedreferenceGlaxoSmithKline. Study EPIP083 (Preliminary report) 2005. http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp
dc.identifier.citedreferenceSantor D.A., Zuroff D.C., Ramsay J.O., Cervantes P., Palacios J.. Examining scale discriminability in the BDI and CES‐D as a function of depressive severity. Psychol Assess. 7: 1995; 131 – 139
dc.identifier.citedreferenceHayes R.D., Sherbourne C.D., Mazel R.M.. The RAND 36‐Item health survey 1.0. Health Econ. 2: 1993; 217 – 227
dc.identifier.citedreferenceMarcus S.M., Flynn H.A., Blow F., Barry K.. A screening study of antidepressant treatment rates and mood symptoms in pregnancy. Arch Women Ment Health. 8: 2005; 25 – 27
dc.identifier.citedreferenceAltshuler L.L., Hendrick V.C.. Pregnancy and psychotropic medication: changes in blood levels. J Clin Psychopharmacol. 16: 1996; Feb 78 – 80
dc.identifier.citedreferenceWisner K.L., Perel J.M., Wheeler S.B.. Tricyclic dosage requirements across pregnancy. Am J Psychiatry. 150: 1993; 1541 – 1552
dc.identifier.citedreferenceNulman I., Rovet J., Stewart D.E., Wolpin J., Pace‐Asciak P., Shuhaiber S., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 159: 2002; 1889 – 1895
dc.identifier.citedreferenceMarcus S.M., Flynn H.A., Blow F., Barry K.L.. Depressive symptoms among pregnant women screened in obstetrics settings. J Women’s Health (Larchmt). 12: 2003; 373 – 380
dc.identifier.citedreferenceKelly R.H., Russo J., Holt V.L., Danielsen B.H., Zatzick D.F., Walter E., et al. Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery. Obstet Gynecol. 100: 2002; 297 – 304
dc.identifier.citedreferenceField T., Diego M., Hernandez‐Reif M.. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev. 29: 2006; 445 – 455
dc.identifier.citedreferenceMcKee M.D., Cunningham M., Jankowski K., Zayas L.. Health‐related functional status in pregnancy: relationship to depression and social support in a multi‐ethnic population. Obstet Gynecol. 97: 2001; 988 – 993
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ijgo248.pdf
Size:
96.49KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.